Luckie M, Khattar R S, Fraser D
Manchester Heart Centre, Manchester Royal Infirmary, Manchester, UK.
Heart. 2009 Aug;95(16):1303-8. doi: 10.1136/hrt.2008.161273. Epub 2009 Feb 12.
Coronary artery stenting is increasingly used as a treatment for coronary artery disease. A period of antiplatelet therapy is mandatory following coronary stenting, in order to minimise the risk of stent thrombosis. About 5% of patients who undergo coronary stenting will require non-cardiac surgery within 12 months, and the management of antiplatelet therapy in this setting is complex, requiring a balance between the risks of both operative haemorrhage and stent thrombosis. The available evidence to guide decision-making in the management of antiplatelet therapy in this setting is reviewed.
冠状动脉支架置入术越来越多地被用作治疗冠状动脉疾病的方法。冠状动脉支架置入术后必须进行一段时间的抗血小板治疗，以将支架血栓形成的风险降至最低。接受冠状动脉支架置入术的患者中约有5%会在12个月内需要进行非心脏手术，在这种情况下抗血小板治疗的管理很复杂，需要在手术出血风险和支架血栓形成风险之间取得平衡。本文综述了在这种情况下指导抗血小板治疗管理决策的现有证据。
